Hengrui dexmedetomidine hydrochloride injection is approved by USA a

Source: drug consistency evaluation 2017-09-21 September 20, 2017, Jiangsu Hengrui Pharmaceutical Co., Ltd., with the specification of 200 μ g / 2ml dexmedetomidine hydrochloride injection, passed the brief new drug application (anda) of FDA drug review and research center Jiangsu Hengrui Pharmaceutical Co., Ltd can produce and sell dexmedetomidine hydrochloride injection to the American public Dexmedetomidine is a α 2-adrenergic receptor agonist Dexmedetomidine hydrochloride injection of Jiangsu Hengrui Pharmaceutical Co., Ltd has been widely used in clinical anesthesia and severe cases since it was listed in 2009 Dexmedetomidine is different from other sedative hypnotics in its mechanism of action It can produce natural non moving eye sleep In a certain dose range, the function of the body's wake-up system still exists During the induction of general anesthesia, it can make the anesthesia induction stable and the intubation response reduced, especially for the patients with hypertension, hyperthyroidism, pheochromocytoma and coronary heart disease, the effect is more significant; it can also make the anesthesia maintenance period easier to manage, the intraoperative hemodynamics more stable, and the postoperative recovery quality higher For patients who need regional block sedation, satisfactory sedation can be obtained, tension and anxiety can be avoided, comfort of patients can be enhanced, and there is no obvious inhibition on respiration [1] For ICU patients, it can alleviate anxiety and fidgety, so as to improve the comfort of patients; and because of its advantages of being easily awakened, patients are easy to cooperate with the corresponding treatment of medical staff [1] According to the lancet report, continuous intravenous infusion of dexmedetomidine after operation can significantly reduce the incidence of delirium in 7 days in elderly patients admitted to ICU after non cardiac surgery, and play a good preventive effect [2] At the same time, in the sleep study of the elderly patients admitted to ICU after non cardiac surgery, dextromethomidine can improve the sleep quality, prolong the sleep time, and improve the sleep structure [3] Reference [1] anesthesiology branch of Chinese Medical Association, clinical application guidance of dexmedetomidine [J], 2013, 93 (35): 2775 ~ 2777 [2] Su x, Meng ZT, Wu XH, et al Dexmedetomidine for prevention of delirium in early patients after non cardiac surgery: a random, double blind, placebo controlled trial [J] The lancet, 2016, 388 (10054): 1893-1902
[3] Wu X H, Cui F, Zhang C, et al Low-dose Dexmedetomidine Improves Sleep Quality Pattern in Elderly Patients after Noncardiac Surgery in the Intensive Care UnitA Pilot Randomized Controlled Trial[J] Anesthesiology: The Journal of the American Society of Anesthesiologists, 2016, 125(5): 979-991.